CareCloud (NASDAQ:CCLD) Azioni

CARECLOUD INC

CareCloud

CareCloud Inc is a healthcare information technology company. The company provides a full suite of proprietary cloud-based solutions and related business services. Its Software-as-a-Service platforms include practice management (PM), electronic health record (EHR), business intelligence, patient experience management (PXM) solutions, and robotic processing automation (RPA) bots, along with complementary software tools and business services such as revenue cycle management (RCM), premiere healthcare consulting and implementation services, and on-demand workforce staffing capabilities for high-performance medical groups and health systems nationwide. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.

CareCloud Inc

CareCloud, Inc. - 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock

CareCloud Inc 11 % Cum Red Perp Pfd Registered Shs Series -A-

TSLA: -6% &#x7C; <a href="https://www.benzinga.com/node/46270992">Tesla shares are trading lower after CEO Elon Musk said he would launch a political party.</a>
&nbsp;
COGT: 25% &#x7C; <a href="https://www.benzinga.com/node/46271019">Cogent Biosciences shares are trading higher after the company announced topline results from Part 2 of the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, showing clinically meaningful and statistically significant improvements across the primary and all key secondary endpoints.</a>
&nbsp;
BULL: -6% &#x7C; <a href="https://www.benzinga.com/node/46271008">Webull shares are trading lower after the company announced a $1 billion standby equity agreement Thursday after the market closed.</a>

Movers

Trading Ideas

BULL

COGT

TSLA

Market-Moving News for July 7th

OR Royalties Inc. ("OR Royalties" or the "Company") (OR: TSX &amp; NYSE) is pleased to provide an update on its second quarter 2025 preliminary deliveries, revenues and cash margin, as well as on its cash and debt positions as at June 30th, 2025. All monetary amounts included in this report are expressed in United States dollars, unless otherwise noted.
PRELIMINARY Q2 2025 RESULTS
OR Royalties earned 19,700 attributable gold equivalent ounces1 ("GEOs") in the second quarter of 2025.
OR Royalties recorded preliminary revenues from royalties and streams of $60.4 million during the second quarter, a quarterly record, and preliminary cost of sales (excluding depletion) of $2.6 million, resulting in a record quarterly cash margin2 of approximately $57.8 million (95.8%).
As at June 30th, 2025, OR Royalties' cash position was approximately $49.6 million, following repayments of $40.0 million on the Company's revolving credit facility during the second quarter. OR Royalties' revolving credit facility was drawn by $35.7 million at the end of June 2025, with an additional amount of $614.3&nbsp;million available to be drawn plus the uncommitted accordion of $200.0 million.

News

OR Royalties Reports Q2 Preliminary Revenues From Royalties And Streams Of $60.4M; Earns 19,700 Attributable GEOs In Q2

IREN Limited (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data=r2RGPOHNIUr0R4k8-W7YQ4vqPTzmujE8M-MBI7EeK5pFK0Czvn3PnkVqz-HXH4HF">IREN</a>) (together with its subsidiaries, "IREN" or "the Company"), today published its monthly update for June 2025.
June Highlights
<ul>
<li>Record monthly revenue and hardware profit3</li>
<li>50 EH/s mid-year target achieved</li>
<li>AI Cloud expanded with ~2.4k Blackwell GPUs</li>
<li>$550m convertible notes offering oversubscribed</li>
<li>US domestic issuer status transition complete</li>
<li>Customer and financing workstreams progressing across AI verticals</li>
</ul>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Key Metrics</td>
<td colspan="2">Jun 25</td>
<td>May 25</td>
</tr>
<tr>
<td>Bitcoin Mining</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Average operating hashrate</td>
<td colspan="2">41.1 EH/s</td>
<td>38.4 EH/s</td>
</tr>
<tr>
<td>Bitcoin mined4</td>
<td colspan="2">620 BTC</td>
<td>627 BTC</td>
</tr>
<tr>
<td>Revenue per Bitcoin mined</td>
<td colspan="2">$105,730</td>
<td>$103,345</td>
</tr>
<tr>
<td>Net electricity cost per Bitcoin mined2</td>
<td colspan="2">($26,259)</td>
<td>($27,033)</td>
</tr>
<tr>
<td>Revenue</td>
<td colspan="2">$65.5m</td>
<td>$64.7m</td>
</tr>
<tr>
<td>Net electricity costs1</td>
<td colspan="2">($16.3m)</td>
<td>($16.9m)</td>
</tr>
<tr>
<td>Hardware profit3</td>
<td colspan="2">$49.2m</td>
<td>$47.8m</td>
</tr>
<tr>
<td>Hardware profit margin5</td>
<td colspan="2">75%</td>
<td>74%</td>
</tr>
<tr>
<td>AI Cloud Services</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td colspan="2">$2.2m</td>
<td>$2.2m</td>
</tr>
<tr>
<td>Net electricity costs1</td>
<td colspan="2">($0.03m)</td>
<td>($0.03m)</td>
</tr>
<tr>
<td>Hardware profit3</td>
<td colspan="2">$2.1m</td>
<td>$2.1m</td>
</tr>
<tr>
<td>Hardware profit margin5</td>
<td colspan="2">98%</td>
<td>98%</td>
</tr>
</tbody>
</table>
</figure>

IREN

IREN Hits Record Revenue in June, Mining 620 Bitcoin and Expands AI Cloud With 2,400 GPUs










Ask ChatGPT

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and maintains $24 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Albertsons Companies, Maintains $24 Price Target

WIIM

Molina shares are trading lower after the company guided Q2 EPS to $5.50 vs the $6.21 estimate and cut its full-year EPS outlook amid rising medical costs.

Cogent Biosciences shares are trading higher after the company announced topline results from Part 2 of the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, showing clinically meaningful and statistically significant improvements across the primary and all key secondary endpoints.

Webull shares are trading lower after the company announced a $1 billion standby equity agreement Thursday after the market closed.

Tesla shares are trading lower after CEO Elon Musk said he would launch a political party.

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) will release earnings results for the second quarter, before the opening <a href="https://www.benzinga.com/quote/JPM/earnings">bell on Tuesday, July 15.</a>
Analysts expect the New York-based company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 1, JPMorgan announced a dividend increase and authorized a new buyback. The company's board announced that it intends to increase the quarterly stock dividend from $1.40 per share to $1.50 per share for the third quarter.
JPMorgan shares gained 1.9% to close at $296.00 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/jpm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating and raised the price target from $280 to $298 on July 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Keith Horowitz maintained a Neutral rating and boosted the price target from $250 to $275 on June 26, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Morgan Stanley analyst Betsy Graseck maintained an Equal-Weight rating and boosted the price target from $236 to $240 on June 23, 2025. This analyst has an accuracy rate of 61%.</li>
<li>B of A Securities analyst Ebrahim Poonawala maintained a Buy rating and raised the price target from $300 to $325 on June 18, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst Mike Mayo maintained an Overweight rating and boosted the price target from $300 to $320 on June 10, 2025. This analyst has an accuracy rate of 70%</li>
</ul>
Considering buying JPM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/JPM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-1024x586.png" alt="" class="wp-image-974060" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

JPMorgan Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">EPWK Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>)</h3>
<ul class="wp-block-list">
<li>On May 27, EPWK Holdings posted a H2 loss of 3 cents per share. The company's stock fell around 15% over the past month and has a 52-week low of $0.41.</li>
<li>RSI Value: 24.5</li>
<li>MKZR Price Action: Shares of EPWK Holdings fell 3.3% to close at $0.50 on Thursday.</li>
<li>Edge Stock Ratings: Value at 35.23. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/EPWK"><img loading="lazy" decoding="async" width="408" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56.png" alt="" class="wp-image-974564" style="width:291px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56.png 408w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56-300x134.png 300w" sizes="(max-width: 408px) 100vw, 408px" /></a></figure>
<h3 class="wp-block-heading">HUYA Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>)</h3>
<ul class="wp-block-list">
<li>On May 13, HUYA posted first-quarter adjusted earnings of 1 cent per share. Mr. Junhong Huang, Acting Co-Chief Executive Officer and Senior Vice President of Huya, commented, &#8220;During the first quarter of 2025, we continued to strengthen our live streaming content ecosystem, deepen collaborations with game companies and content platforms, and effectively implement our strategic business transformation.&#8221; The company's stock fell around 40% over the past month and<a href="https://www.benzinga.com/quote/HUYA"> has a 52-week low</a> of $0.080.</li>
<li>RSI Value: 26.1</li>
<li>HUYA Price Action: Shares of HUYA closed at $2.47 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">HUYA stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="920" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57.png" alt="" class="wp-image-974568" style="width:710px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57-768x694.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Gibo Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>)</h3>
<ul class="wp-block-list">
<li>On June 30, GIBO Holdings announced the successful testing of its AI-driven engine, GIBO Click, on uDrama, a rising star in the global short drama landscape.. The company's stock fell around 96% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/GIBO">low of $0.082</a>.</li>
<li>RSI Value: 10.1</li>
<li>GIBO Ltd Price Action: Shares of Gibo Holdings dipped 29.6% to close at $0.084 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">RETO shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="882" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58.png" alt="" class="wp-image-974576" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58-768x702.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

EPWK

GIBO

HUYA

Top 3 Tech And Telecom Stocks That Are Set To Fly In Q3

<ul>
<li>Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population.</li>
<li>Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo.</li>
<li>Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population.</li>
<li>Bezuclastinib NDA submission to FDA expected by end of 2025; strong financial position with $237 million current cash balance and access up to an additional $350 million via recently announced debt facility with SLR Capital Partners.</li>
<li>On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025</li>
</ul>

Biotech

Health Care

General

Cogent Biosciences Announces Topline Results From Part 2 Of The SUMMIT Trial Of Bezuclastinib For Non-advanced Systemic Mastocytosis, Demonstrating Clinically Meaningful And Highly Statistically Significant Improvements Across The Primary And All Key Secondary Endpoints

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox
TNX-801 confers durable protection after a single dose
TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses
CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) ("Tonix" or the "Company"), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Sina Bavari, PhD, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present new data on TNX-801 (recombinant horsepox virus, live vaccine) at the upcoming Vaccine Congress 2025.
TNX-801 is a minimally replicative, attenuated live virus vaccine candidate designed to generate durable humoral and cellular immunity after a single dose. Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens.
Dr. Bavari will present the safety, immunogenicity, and efficacy findings to date and describe Tonix's plans to advance the TNX-801 platform into clinical trials to protect against mpox and other viral diseases.

TNXP

Tonix Pharma To Present New Data On TNX-801, Recombinant Horsepox Virus, Live Vaccine, At Upcoming Vaccine Congress 2025

The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>), the nation's largest franchisor of chiropractic care through The Joint Chiropractic&#xAE; network, closed the sale of 31 corporate owned and managed clinics and associated franchise licenses in Arizona and New Mexico to Joint Ventures, LLC in exchange for $8.3 million in cash and the regional developer (RD) territory rights of the Northwest region that generated $855,000 in royalties and franchise fees over the 12 months ended March 31, 2025. "Our goal for the refranchising initiative is to strengthen and simplify our business, while ensuring our clinics go to proven franchise operators that can improve performance and grow within their regions," said The Joint Corp.'s President, Chief Executive Officer and Director Sanjiv Razdan. "We are very happy that Joint Ventures, one of our strongest franchisees, is purchasing 31 clinics in Arizona and New Mexico. As part of the consideration for the clinics, we are acquiring Joint Ventures' regional developer rights for the Northwest region, covering 46 existing franchised clinics and 30 sites for future clinic development. By acquiring RD rights, we will reduce commission obligations and increase operating margin, as these clinics incurred $855,000 in royalties and commissions under these RD rights in the trailing twelve months ended March 31, 2025. By increasing their stake in The Joint, existing franchisees are validating our initiatives to strengthen the patient experience, drive revenue and reduce operational costs. We expect to deploy our expanding working capital to generate value for stockholders."

JYNT

The Joint Sells 31 Clinics for $8.3M, Gains Control of Profitable Northwest Franchise Region

Heidmar Maritime Holdings Corp. (the "Company" or "Heidmar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) today announces its first vessel acquisition, making it a strategic milestone in the Company's project development and growth strategy.
Heidmar has entered into an agreement to acquire C/V A. Obelix, a 1,702 TEU cellular/gearless feeder container vessel, built in 2008 at Wadan/Aker Yards, Wismar Germany. C/V A. Obelix is classed by Lloyd's Register and has been strengthened for Ice Class II operations. The vessel is powered by a two-stroke main engine and is equipped with a bow thruster, allowing for a high degree of maneuverability and independence in port operations, and a high-capacity 330-plug reefer system. The vessel's next drydock is scheduled for 2028 allowing for three clear years of operations with no projected upfront maintenance expense.
Heidmar is acquiring its interest in the vessel from a related party at an aggregate purchase price of $25.25 million. The security of the charter revenue and the end-of-life recycling price are expected to effectively cover the cost of the acquisition in case of the high EBITDA scenario.

Heidmar Maritime Agrees To Acquire Cellular/Gearless Feeder Container Vessel, C/V A. Obelix, For $25.25M

Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sand#NYSE">SAND</a>) (TSX:SSL) is pleased to announce that the Company has entered into a definitive arrangement agreement with Royal Gold Inc.
Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SSL#TSX">SSL</a>) is pleased to announce that the Company has entered into a definitive arrangement agreement with Royal Gold Inc. ("Royal Gold"), pursuant to which Royal Gold will acquire all of the issued and outstanding common shares of Sandstorm (the "Sandstorm Shares") in an all-share transaction with an implied value of approximately $3.5&nbsp;billion (the "Sandstorm Transaction"). Sandstorm shareholders will receive 0.0625 of a share of common stock of Royal Gold (each whole share, a "Royal Gold Share") for each Sandstorm Share held, implying a 21% premium to the 20-day volume-weighted average price ("VWAP") of the Sandstorm Shares for the period ended July 3, 2025, and a 17% premium to the closing price of the Sandstorm Shares on the New York Stock Exchange (the "NYSE") on July 3, 2025. Upon closing, existing Royal Gold and Sandstorm shareholders will own approximately 77% and 23%, of the issued and outstanding Royal Gold Shares on a fully diluted basis.

RGLD

SAND

Sandstorm Gold Enters Agreement With Royal Gold, Under Which Royal Gold Will Acquire All Issued And Outstanding Shares Of Sandstorm In All-Share Deal With Implied Value Of $3.5B

NTRA

Natera Highlights Clinical Results From CIRCULATE-Japan Study, Demonstrating Latitude MRD Assay's Prognostic And Predictive Value

LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, intended to enable earlier patient access to therapies with expedited clinical development timelines.

LXEO

The FDA Grants Breakthrough Therapy Designation To Lexeo Therapeutics' LX2006 Based On Clinical Evidence Generated On Both Cardiac And Neurologic Measures Of Friedreich Ataxia

The FDA Approves Expanding The Instructions For Use Labeling For Boston Scientific's Farapulse Pulsed Field Ablation System To Include Approval For The System For Drug-refractory, Symptomatic Persistent Atrial Fibrillation

CRGO

SEKO Logistics Expands Freightos Integration To Unify Global Air And Ground Quoting And Booking Workflows

<a href="https://www.globenewswire.com/Tracker?data=xcP7wf83V4GEKHc3LIsF5CN7ExOTRlN2vdGpSbVRyRF1wxXQcbFUUUf0r3adWNQWJrYRos-xPecs45_LouQic97ZEDik3Cj2_ZVnXTh4QV0=">BeyondSpring Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) today announced publication of a human clinical study in&nbsp;Med&nbsp;(Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces dendritic cell (DC) maturation and elicits tumor responses in patients across multiple cancer types who had failed prior ICI therapy. The study also identified a potential biomarker—baseline GEF-H1 immune signature—that may enable patient pre-selection and clinical response prediction.
"These results offer early but important signals that Plinabulin's dendritic cell maturation mechanism could play a pivotal role in reversing ICI-acquired resistance," said Dr. Steven Lin, M.D., Ph.D., corresponding author and Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center. "The ability of Plinabulin to activate the immune system in this setting is both scientifically intriguing and clinically promising—particularly given the durability of responses in some heavily pretreated patients."
Dr. Lin added, "It is especially noteworthy that Plinabulin combination demonstrated the best responses in non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma."
"This study builds upon the seminal work of Nobel Laureate Dr. Ralph Steinman and Dr. Ira Mellman, who helped define the essential role of dendritic cells in immune activation," said Lan Huang, Ph.D., Co-Founder, Chairman, and CEO of BeyondSpring. "Plinabulin's ability to drive dendritic cell maturation and induce immune responsiveness offers a potential breakthrough strategy for patients who are refractory or relapsed on checkpoint inhibitors. We are committed to advancing Plinabulin's development in partnership with pioneering cancer research institutions like MD Anderson."
Triple I/O Combination Study Highlights
This investigator-initiated, Phase 1 translational trial (NCT04902040) evaluated a triple immunotherapy approach combining Plinabulin, radiation (RT), and anti-PD-1 checkpoint inhibitors in patients with eight cancer types who are refractory or relapsed on prior ICI therapy. RT was administered only during the first cycle. The primary endpoint was tumor response in non-irradiated lesions.
<ul>
<li>Clinical Results Nineteen patients received the combination regimen—14 on pembrolizumab and 5 on nivolumab. Tumor responses were evaluable in 13 ICI-relapsed patients across eight tumor types. Objective response rate (ORR) was 23%, and disease control rate (DCR) was 54%. Clinically meaningful benefits (PR, partial response; SD, stable disease) were observed in NSCLC (2/2), HNSCC (2/3), and Hodgkin lymphoma (2/2). Both Hodgkin lymphoma patients had durable responses exceeding 19 months despite 12–16 prior lines of therapy.</li>
<li>Mechanism Confirmation Plinabulin triggered DC maturation post-RT via GEF-H1 signaling. Flow cytometry of whole blood revealed increased expression of DC maturation markers (CCR7, CD80, CD83) and a shift in monocyte subpopulations from classical to proinflammatory phenotype in responders.</li>
<li>Biomarker Insight Single-cell RNA sequencing differentiated responders from non-responders and identified baseline GEF-H1 immune gene expression as a potential predictive biomarker for Plinabulin response. &nbsp;</li>
</ul>

BYSI

BeyondSpring Drug Triggers Immune Response in Patients Who Failed Prior Cancer Immunotherapy

Press Releases

CareCloud Announces Preferred Stock Dividend Payments

CareCloud Delivers Growth and Strong Cash Flow in Q1 2025, Advances AI and Acquisition Strategy

CareCloud Named "Top Healthcare IT Pick for 2025" by Maxim Group; AI Initiative Recognized as Key Growth Driver

Investing in Smarter Healthcare: The New Era of AI-Driven Medicine

Small Cap

Opinion

AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge

CareCloud Announces Results from Annual Shareholders' Meeting

CareCloud to Present on AI Innovation at Maxim Group's 2025 Virtual Tech Conference on June 3, 2025

CareCloud Announces Potential Resignation of its Audit Firm

CareCloud Confirms ICFR Attestation Requirement Following $85.1 Million Public Float Milestone; Launches Audit Firm Search

CareCloud Joins Russell Microcap Index as Common Stock Price Rises 70% During Q2 2025

Comments

CareCloud

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO